ArticleCancer management and research2026
Impact of Adjuvant Chemotherapy on the Prognosis in Elderly Patients with Stage II and III Colorectal Cancer: A Retrospective Multicenter Study.
Article in Cancer management and research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: The objective of this retrospective multicenter study was to evaluate the efficacy of adjuvant chemotherapy (adCTx) following curative resection in patients aged ≥70 years with colorectal cancer (CRC) and to compare the outcomes of monotherapy versus combination chemotherapy. Methods: Data from 1183 patients with stage II or III CRC who underwent surgery at five Hallym University-affiliated hospitals in Korea between 2012 and 2022 were retrospectively analyzed. Patients were divided into two groups based on adjuvant chemotherapy status (adCTx (+) vs adCTx (-)). Those receiving adCTx were further stratified into 5-fluorouracil (5-FU) monotherapy or 5-FU plus oxaliplatin combination therapy. Multivariable Cox regression was used to estimate adjusted hazard ratios (HRs) for overall survival (OS) and recurrence-free survival (RFS). Results: Of the 1183 patients, 555 received adCTx and 628 did not. Patients in the adCTx (+) group showed significantly better 5-year OS (88.6% vs 75.7%, P < 0.001) and RFS (66.5% vs 58.6%, P < 0.001). In multivariable analysis, adCTx was independently associated with improved OS (HR 0.33, 95% CI 0.23-0.48, P < 0.001) and RFS (HR 0.59, 95% CI 0.47-0.76, P < 0.001). Among patients receiving chemotherapy, there was no significant difference in OS or RFS between monotherapy and combination therapy. In stage II patients with high-risk factors, adCTx (+) was associated with better OS (P = 0.002) and RFS (P = 0.006), but the number of agents did not provide additional benefit. Conclusion: In this study of patients aged ≥70 years with stage II or III CRC, adjuvant chemotherapy was associated with improved OS and RFS. No significant differences in oncologic outcomes were observed between monotherapy and combination therapy. These findings suggest a potential benefit of adjuvant chemotherapy in selected elderly patients; however, prospective randomized studies are needed to confirm these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.